{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:52:34Z","timestamp":1794739954462,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijcard.2023.131598","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:57:16Z","timestamp":1700236636000},"page":"131598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States"],"prefix":"10.1016","volume":"398","author":[{"given":"Anson T.C.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"DiDomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kibum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2023.131598_bb0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ijcard.2023.131598_bb0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC. Heart Failur."},{"key":"10.1016\/j.ijcard.2023.131598_bb0015","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug Discovery and Development in rare Diseases: taking a closer look at the Tafamidis Story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"6","key":"10.1016\/j.ijcard.2023.131598_bb0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"1","key":"10.1016\/j.ijcard.2023.131598_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-Term Survival with Tafamidis in patients with Transthyretin Amyloid Cardiomyopathy","volume":"15","author":"Elliott","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2023.131598_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of Cardiovascular Hospitalization and death in patients with Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial ATTR-ACT)","volume":"148","author":"Miller","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131598_bb0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of Tafamidis on Health-Related Quality of Life in patients with Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0040","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/cer-2021-0071","article-title":"Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"J. Comparat. Effectiv. Res."},{"key":"10.1016\/j.ijcard.2023.131598_bb0045","series-title":"Micromedex RED BOOK","year":"2022"},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0050","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.ijcard.2023.131598_bb0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40119-019-00160-8","article-title":"Diagnosis of Amyloidosis: a survey of Current Awareness and Clinical challenges among Cardiologists in Switzerland","volume":"9","author":"Mircsof","year":"2020","journal-title":"Cardiol. Therap."},{"issue":"Suppl_1","key":"10.1016\/j.ijcard.2023.131598_bb0060","doi-asserted-by":"crossref","first-page":"A15674","DOI":"10.1161\/circ.146.suppl_1.15674","article-title":"Utilization rates of Follow-up Testing with Pyp Scan and Cardiac Mri, and Clinical and Demographic Determinants of their use among patients with Echocardiographic Features of Cardiac Amyloidosis: a Population-based Case Control Study","volume":"146","author":"Fessehaie","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2023.131598_bb0065","first-page":"19","article-title":"The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical Centre","volume":"29","author":"Dower","year":"2022","journal-title":"British J. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0070","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart failure with Preserved Ejection Fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2023.131598_bb0075","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.2967\/jnumed.122.264041","article-title":"Prevalence and Outcomes of Cardiac Amyloidosis in All-Comer Referrals for Bone Scintigraphy","volume":"63","author":"Nitsche","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0080","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00392-017-1137-7","article-title":"Epidemiology of heart failure in Germany: a retrospective database study","volume":"106","author":"St\u00f6rk","year":"2017","journal-title":"Clin. Res. Cardiol. : Off. J. German Card. Soc."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131598_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed Diagnosis and Misdiagnosis for patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): a Targeted Literature Review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol. Therap."},{"key":"10.1016\/j.ijcard.2023.131598_bb0090","series-title":"Tafamidis: Capsule 61 mg; Vyndamax\u00ae Public Summary Document (PSD) September 2021 PBAC Meeting","year":"2021"},{"issue":"7","key":"10.1016\/j.ijcard.2023.131598_bb0095","doi-asserted-by":"crossref","DOI":"10.2196\/17846","article-title":"Telemonitoring Versus Usual Care for Elderly Patients with Heart Failure Discharged from the Hospital in the United States: Cost-Effectiveness","volume":"8","author":"Jiang","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"issue":"4","key":"10.1016\/j.ijcard.2023.131598_bb0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40256-022-00526-9","article-title":"Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in patients with Transthyretin Amyloid Cardiomyopathy","volume":"22","author":"Rozenbaum","year":"2022","journal-title":"American J. Cardiovas. Drugs\u202f: Drugs, Dev., Other Intervent."},{"key":"10.1016\/j.ijcard.2023.131598_bb0105","author":"National Vital Statistics Reports","year":"2020","journal-title":"U.S. State Life Tables"},{"key":"10.1016\/j.ijcard.2023.131598_bb0110","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ (Clin. Res. ed.)"},{"issue":"suppl_1","key":"10.1016\/j.ijcard.2023.131598_bb0115","article-title":"Ten year survival by NYHA functional class in heart failure outpatients referred to specialized multidisciplinary heart failure clinics 1999 to 2011","volume":"34","author":"Arnold","year":"2013","journal-title":"Eur. Heart J."},{"issue":"Suppl_1","key":"10.1016\/j.ijcard.2023.131598_bb0120","first-page":"1505","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"34","author":"Lauppe","year":"2022","journal-title":"ESC Heart Failur"},{"key":"10.1016\/j.ijcard.2023.131598_bb0125","series-title":"Physician\/Supplier Procedure Summary","year":"2021"},{"key":"10.1016\/j.ijcard.2023.131598_bb0130","unstructured":"TrueHealthLabs.com. Free Kappa and Lambda Light Chains Plus Ratio, Quantitative, Serum. Accessed March 25, 2022. https:\/\/truehealthlabs.com\/product\/free-kappa-and-lambda-light-chains-plus-ratio-quantitative-serum\/."},{"key":"10.1016\/j.ijcard.2023.131598_bb0135","unstructured":"TrueHealthLabs.com. Immunofixation (IFE), Serum. Accessed March 25, 2022. https:\/\/truehealthlabs.com\/product\/immunofixation-ife-serum\/."},{"key":"10.1016\/j.ijcard.2023.131598_bb0140","unstructured":"Partners HealthCare. Order Transthyretin Amyloidosis Test. Accessed September 7, 2022. https:\/\/personalizedmedicine.partners.org\/Laboratory-For-Molecular-Medicine\/Ordering\/Cardiomyopathy\/TTR-Gene.aspx."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131598_bb0145","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: a Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ijcard.2023.131598_bb0150","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131598_bb0155","series-title":"Canadian Agency for Drugs and Technologies in Health: Ottawa, ON","author":"Pharmacoeconomic Review Report: Tafamidis","year":"2020"},{"key":"10.1016\/j.ijcard.2023.131598_bb0160","series-title":"Costs of Emergency Department Visits in the United States, 2017. HCUP Statistical Brief #268","author":"Moore","year":"2020"},{"key":"10.1016\/j.ijcard.2023.131598_bb0165","series-title":"Expenses for Office-Based Physician Visits by Specialty and Insurance Type, 2016 - Statistical Brief #517","author":"Machlin","year":"2018"},{"key":"10.1016\/j.ijcard.2023.131598_bb0170","unstructured":"Agency for Healthcare Research and Quality,Healthcare Cost & Utilization Project (HCUP) Nationwide HCUP Database, Rockfille, MD. Accessed September 7, 2022. Available at: https:\/\/hcup-us.ahrq.gov\/databases.jsp."},{"key":"10.1016\/j.ijcard.2023.131598_bb0175","unstructured":"U.S. Bureau of Labor Statistics, Consumer Price Index for All Urban Consumers: Medical Care in U.S. City Average [CPIMEDSL], retrieved from FRED, Federal Reserve Bank of St. Louis; https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL. Accessed September 7, 2022."},{"issue":"5","key":"10.1016\/j.ijcard.2023.131598_bb0180","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ehjqcco\/qcab031","article-title":"Health Impact of Tafamidis in Transthyretin Amyloid Cardiomyopathy patients: an Analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the Open-Label long-term Extension Studies","volume":"8","author":"Rozenbaum","year":"2022","journal-title":"European Heart J. Qualit. Care Clin. Outcome."},{"issue":"15","key":"10.1016\/j.ijcard.2023.131598_bb0185","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0190","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13598","article-title":"Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"issue":"18","key":"10.1016\/j.ijcard.2023.131598_bb0200","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026308","article-title":"Modeling the cost and Health Impacts of Diagnostic strategies in patients with Suspected Transthyretin Cardiac Amyloidosis","volume":"11","author":"Ge","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"14","key":"10.1016\/j.ijcard.2023.131598_bb0205","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2217\/cer-2022-0120","article-title":"The next generation of rare disease drug policy: ensuring both innovation and affordability","volume":"11","author":"Pearson","year":"2022","journal-title":"J. Comparat. Effectiven. Res."},{"issue":"10","key":"10.1016\/j.ijcard.2023.131598_bb0210","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to Identify increased risk of Transthyretin Amyloid Cardiomyopathy in Heart failure with Preserved Ejection Fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ijcard.2023.131598_bb0215","article-title":"Implementing a Machine-Learning-adapted Algorithm to Identify possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center. Clinical medicine insights","volume":"16","author":"Mitchell","year":"2022","journal-title":"Cardiology"},{"issue":"7","key":"10.1016\/j.ijcard.2023.131598_bb0220","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s10554-021-02190-7","article-title":"Deep-learning-based cardiac amyloidosis classification from early acquired pet images","volume":"37","author":"Santarelli","year":"2021","journal-title":"Int. J. Card. Imaging"},{"issue":"1","key":"10.1016\/j.ijcard.2023.131598_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ehf2.13693","article-title":"99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Tahara","year":"2022","journal-title":"ESC Heart Failur."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131598_bb0230","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40273-021-01091-w","article-title":"Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart failure with Reduced Ejection Fraction following a Worsening Heart failure event from a US Medicare Perspective","volume":"39","author":"Alsumali","year":"2021","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1016\/j.ijcard.2023.131598_bb0235","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000525883","article-title":"Estimating the effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III patients with Transthyretin Amyloid Cardiomyopathy in the Presence of death","volume":"147","author":"Li","year":"2022","journal-title":"Cardiology"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323016881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323016881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:04:10Z","timestamp":1759093450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323016881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"alternative-id":["S0167527323016881"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131598","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131598"}}